Mobility for All?

Publication Date

2018

Journal Title

J Am Acad Child Adolesc Psychiatry

Abstract

© 2018 American Academy of Child and Adolescent Psychiatry Substantial numbers of children and adolescents are treated with second-generation antipsychotic medications (SGAs), and the cardiometabolic adverse effects of this medication class have raised concerns.1In the October 2017 issue of the Journal, Handen et al.2published a 16-week open-label extension study of youth 6 to 17 years of age with autism spectrum disorder treated with liquid metformin after a 16-week double-blinded, placebo-controlled clinical efficacy trial. The acute-phase and open-label extension trials demonstrated that liquid metformin was well tolerated, and significant improvements in body mass index z-scores were observed in the metformin-metformin and placebo-metformin groups.2Handen et al.2concluded that metformin can be effective for decreasing weight gain associated with SGA use and maintaining prior improvement in children and adolescents with autism spectrum disorder.

Volume Number

57

Issue Number

10

Pages

792 - 793

Document Type

Article

Status

Faculty

Facility

School of Medicine

Primary Department

Psychiatry

Additional Departments

Molecular Medicine

PMID

30274654

DOI

10.1016/j.jaac.2018.06.019

For the public and Northwell Health campuses

Share

COinS